EUVIMEDEUVIMED entdecken
Crossref

Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy ‐induced bone loss

Yansi Xian, Yijie Gao, Yiji Su, Yuangang Su, Haoyu Lian, Xiaoliang Feng, Zhijuan Liu, Jinmin Zhao, Jiake Xu, Qian Liu iD, Fangming Song iD

Phytotherapy Research · 2024

DOI: 10.1002/ptr.8141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, 2024. Verfasst von Yansi Xian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Key Laboratory of Regenerative Medicine, Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, N…. Hauptthemen laut MEDLINE: Bone Resorption, Caffeic Acids, Osteoporosis, Succinates. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province-Science Fund for Distinguished Young Scholars Program, Natural Science Foundation of Guangxi Province-Key Program Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Osteoporosis, a systemic metabolic bone disease, is characterized by the decline of bone mass and quality due to excessive osteoclast activity. Currently, drug‐targeting osteoclasts show promising therapy for osteoporosis. In this study, we investigated the effect of cichoric acid (CA) on receptor activator of nuclear kappa‐B ligand (RANKL)‐induced osteoclastogenesis and the bone loss induced by ovariectomy in mice. Experimental Procedure Molecular docking technologies were employed to examine the interaction between CA and RANKL. CCK8 assay was used to evaluate the cell viability under CA treatment. TRAcP staining, podosome belt staining, and bone resorption assays were used to test the effect of CA on osteoclastogenesis and osteoclast function. Further, an OVX‐induced osteoporosis mice model was employed to identify the effect of CA on bone loss using micro‐CT scanning and histological examination. To investigate underlying mechanisms, network pharmacology was applied to predict the downstream signaling pathways, which were verified by Western blot and immunofluorescence staining. Key Results The molecular docking analysis revealed that CA exhibited a specific binding affinity to RANKL, engaging multiple binding sites. CA inhibited RANKL‐induced osteoclastogenesis and bone resorption without cytotoxic effects. Mechanistically, CA suppressed RANKL‐induced intracellular reactive oxygen species, nuclear factor‐kappa B, and mitogen‐activated protein kinase pathways, followed by abrogated nuclear factor activated T‐cells 1 activity. Consistent with this finding, CA attenuated post‐ovariectomy‐induced osteoporosis by ameliorating osteoclastogenesis. Conclusions and Implications CA inhibited osteoclast activity and bone loss by targeting RANKL. CA might represent a promising candidate for treating osteoclast‐related diseases, such as osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone ResorptionCaffeic AcidsOsteoporosisSuccinatesAnimalsFemaleHumansMiceCell DifferentiationMice, Inbred C57BLMolecular Docking SimulationNF-kappa BOsteoclastsOsteogenesisOvariectomyRANK Ligand

Stichwörter der Autor:innen

RANKLcichoric acidnetwork pharmacologyosteoclast

Substanzen

Caffeic Acidschicoric acidNF-kappa BRANK LigandSuccinates

Autor:innen und Institutionen

  • Guangxi Key Laboratory of Regenerative Medicine, Orthopaedics Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning, China.
  • Division of Sports Medicine and Adult Reconstructive Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • School of Biomedical Sciences, the University of Western Australia, Perth, Australia.
  • Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

ORCID-Profile: Qian Liu, Fangming Song

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangxi Province-Science Fund for Distinguished Young Scholars Program
  • Natural Science Foundation of Guangxi Province-Key Program Program
  • Guangxi Science and Technology Base and Talent Special Project
  • Nanning Qingxiu District Science and Technology Bureau key research and development projects
  • Specific Research Project of Guangxi for Research Bases and Talents

Zitieren

APA

Xian, Y., Gao, Y., Su, Y., Su, Y., Lian, H., Feng, X., Liu, Z., Zhao, J., Xu, J., Liu, Q., & Song, F. (2024). Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy ‐induced bone loss. Phytotherapy Research. https://doi.org/10.1002/ptr.8141

Vancouver

Xian Y, Gao Y, Su Y, Su Y, Lian H, Feng X, et al. Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy ‐induced bone loss. Phytotherapy Research. 2024. doi:10.1002/ptr.8141

BibTeX
@article{Xian2024,
  author = {Xian, Yansi and Gao, Yijie and Su, Yiji and Su, Yuangang and Lian, Haoyu and Feng, Xiaoliang and Liu, Zhijuan and Zhao, Jinmin and Xu, Jiake and Liu, Qian and Song, Fangming},
  title = {Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy ‐induced bone loss},
  journal = {Phytotherapy Research},
  year = {2024},
  doi = {10.1002/ptr.8141}
}
Kostenlos starten →